PT Kalbe Farma Tbk. (KLBF.JK)
- Previous Close
1,440.00 - Open
1,450.00 - Bid 1,440.00 x --
- Ask 1,450.00 x --
- Day's Range
1,420.00 - 1,455.00 - 52 Week Range
985.00 - 1,795.00 - Volume
32,101,300 - Avg. Volume
49,864,785 - Market Cap (intraday)
66.186T - Beta (5Y Monthly) 0.04
- PE Ratio (TTM)
19.86 - EPS (TTM)
73.01 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield 31.00 (2.15%)
- Ex-Dividend Date May 29, 2024
- 1y Target Est
1,629.33
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic divisions. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is based in Jakarta, Indonesia.
www.kalbe.co.id12,841
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KLBF.JK
View MorePerformance Overview: KLBF.JK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLBF.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLBF.JK
View MoreValuation Measures
Market Cap
66.19T
Enterprise Value
62.03T
Trailing P/E
19.85
Forward P/E
19.46
PEG Ratio (5yr expected)
1.78
Price/Sales (ttm)
2.02
Price/Book (mrq)
2.81
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
12.99
Financial Highlights
Profitability and Income Statement
Profit Margin
10.15%
Return on Assets (ttm)
8.96%
Return on Equity (ttm)
13.62%
Revenue (ttm)
33.11T
Net Income Avi to Common (ttm)
3.36T
Diluted EPS (ttm)
73.01
Balance Sheet and Cash Flow
Total Cash (mrq)
4.69T
Total Debt/Equity (mrq)
2.11%
Levered Free Cash Flow (ttm)
2.38T